The role of inflammation in bladder cancer

Advances in Experimental Medicine and Biology

Volumn 816, Issue , 2014, Pages 183-196

  Gakis, Georgios ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ATORVASTATIN; CELECOXIB; CYCLOOXYGENASE 2; NEUROPILIN; NEUROTROPHIN RECEPTOR P75; OSTEONECTIN; PLACEBO; SIX TRANSMEMBRANE EPITHELIAL ANTIGEN OF THE PROSTATE PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; CYCLOOXYGENASE 1; IMMUNOGLOBULIN G; INTERLEUKIN 2;

ANTIGEN PRESENTING CELL; ARTICLE; BLADDER CANCER; BLADDER CARCINOGENESIS; CANCER PREVENTION; CANCER STAGING; CANCER STEM CELL; CANCER SURVIVAL; CELL PROLIFERATION; CYTOKINE STORM; DRUG EFFICACY; ENZYME ACTIVATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INFLAMMATORY CELL; LYMPHOCYTE DIFFERENTIATION; MALIGNANT TRANSFORMATION; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTAGLANDIN METABOLISM; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TUMOR INVASION; UPREGULATION; CANCER GROWTH; CELL INVASION; CELL SURVIVAL; CELL TRANSFORMATION; CELLULAR IMMUNITY; CYTOKINE RELEASE; TH17 CELL; TUMOR VASCULARIZATION;

EID: 84959200490     PISSN: 00652598     EISSN: 22148019     Source Type: Book Series    
DOI: 10.1007/978-3-348-837-8_8     Document Type: Article

References (47)

1. Abdollah F, Gandaglia G, Thuret R, Schmitges J, Tian Z, Jeldres C, Passoni NM, Briganti A, Shariat SF, Perrotte P, Montorsi F, Karakiewicz PI, Sun M (2013) Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis. Cancer Epidemiol. doi:10.1016/j.canep.2013.02.002
2. Ajili F, Kourda N, Darouiche A, Chebil M, Boubaker S (2013) Prognostic value of tumor-associated macrophages count in human non-muscle-invasive bl adder cancer treated by BCG immunotherapy. Ultrastruct Pathol 37(1):56-61
3. Azumi M, Kobayashi H, Aoki N, Sato K, Kimura S, Kakizaki H, Tateno M (2010) Sixtransmembrane epithelial antigen of the prostate as an immunotherapeutic target for renal cell and bladder cancer. J Urol 183(5):2036-2044
4. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J, Rouprêt M (2011 ) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 59(6):997-1008
5. Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow? Lancet 357(9255):539-545
6. Boströ m PJ, Aaltonen V, Söderström KO, Uotila P, Laato M (2001a ) Expression of cyclooxygenase-1 and-2 in urinary bladder carcinomas in vivo and in vitro and prostaglandin E2 synthesi s in cultured bladder cancer cells. Pathology 33(4):469-474
7. Boströ m PJ, Uotila P, Rajala P, Nurmi M, Huhtaniemi I, Laato M (2001b ) Interferon-alpha inhibits cyclooxygenase-1 and stimulates cyclooxygenase-2 expression in bladder cancer cells in vitro. Urol Res 29(1):20-24
8. Cekic C, Sag D, Li Y, Theodorescu D, Strieter RM, Linden J (2012) Adenosine A2B receptor blockade slows growth of bladder and breast tumors. J Immunol 188(1):198-205
9. Chi LJ, Lu HT, Li GL, Wang XM, Su Y, Xu WH, Shen BZ (2010) Involvement of T helper type 17 and regulatory T cell activity in tumour i mmunology of bladder carcinoma. Clin Exp Immunol 161(3):480-489
10. Cholesterol Treatment Trialists' (CTT) Collaboration (2012) Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data fr om 175,000 people in 27 randomised trials of statin therapy. PLoS One 7(1):e29849
11. Dufresne M, Dumas G, Asselin E, Carrier C, Pouliot M, Reyes-Moreno C (2011) Pro-inflammatory type-1 and anti-in flammatory type-2 macrophages differentially modulate cell survival and invasion of human bladder carcinoma T24 cells. Mol Immunol 48(12-13):1556-1567
12. Edin S, Wikberg M, Dahlin AM, Rutegard J, Oberg A , Oldenborg PA, Palmqvist R (2012) The distribution of macrophages with a M1 or M2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer. PLoS ONE 7(10):e47045
13. Eruslanov E, Daurkin I, Vieweg J, Daaka Y, Kusmartsev S (2011) Aberrant PGE2 metabolism in bladder tumor microenvironment promotes immunosuppressive phenotype of tumor-infiltrating myeloid cells. Int Immunopharmacol 11(7):84 8-855
14. Eruslanov E, Neuberger M, Daurkin I, Perrin GQ, Algood C, Dahm P, Rosser C, Vieweg J, Gilbert SM, Kusmartsev S (2012) Circulating and tumor-infiltrating myeloid cell subsets in patients with bla dder cancer. Int J Cancer 130(5):1109-1119
15. Gakis G, Kruck S, Stenzl A (2010) Can the burden of follow-up in low-grade noninvasive bladder cancer be reduced by photodynamic diagnosis, perioperative instillations, imaging, and urine markers? Curr Opin Urol 20(5):388-392
16. Gakis G, Todenhö fer T, Stenzl A (2011a) The prognostic value of hematological and systemic inflammatory disorders in invasive bladder cancer. Curr Opin Urol 21(5):428-433
17. Gakis G, T odenhö fer T, Renninger M, Schilling D, Sievert KD, Schwentner C, Stenzl A (2011b) Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard patholog ical risk factors: the TNR-C score. BJU Int 108(11):1800-1805
18. Gakis G, Efstathiou JA, Lerner SP, Cookson MS, Keegan KA, Guru KA, Shipley WU, Heidenreich A, Schoenberg MP, Sagalosw ky AI, Soloway MS, Stenzl A (2013) ICUD-EAU International Consultation on bladder cancer 2012: radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol 63(1):45-57
19. Gildea JJ, Seraj MJ, Oxford G, Harding MA, Hampton GM, Moskaluk CA, Frierson HF, Conaway MR, Theodorescu D (2002) RhoGDI2 is an invasion and metastasis suppressor gene in human cancer. Cancer Res 62(22):6418-6423
20. Grunewald TG, Bach H, Cossarizza A, Matsumoto I (2012) The STEAP protein family: versatile oxidoreductases and targets for cancer immunotherapy with overlapping and distinct cellular function s. Biol Cell 104(11):641-657
21. Ishioka J, Saito K, Sakura M, Yokoyama M, Matsuoka Y, Numao N, Koga F, Masuda H, Fujii Y, Kawakami S, Kihara K (2012) Development of a nomogram incorporating serum C-reactive protein level to predict overall survival of patients with advanced urothelial carcinoma and its evaluation by decision curve analysis. Br J Cancer 107(7):1031-1036
22. Kawai K, Miyazaki J, Joraku A, Nishiyama H, Akaza H (2013) Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine. Cancer Sci 104(1):22-27
23. K hwaja F, Allen J, Lynch J, Andrews P, Djakiew D (2004) Ibuprofen inhibits survival of bladder cancer cells by induced expression of the p75NTR tumor suppressor protein. Cancer Res 64(17):6207-6213
24. Ledue TB, Weiner DL, Sipe JD, Poulin SE, Collins MF, Rifai N (1998) Analytical evaluation of particle-enhanced immunonephelometric assays for C-reactive protein, serum amyloid A and mannose-binding protein in human serum. Ann Clin Biochem 35(Pt 6):745-753
25. Liang PY, Li HY, Zhou ZY, Jin YX, Wang SX, Peng XH, Ou SJ (2013) Overexpression of immunoglobulin G prompts cell proliferation and inhibits cell apoptosis in human ur othelial carcinoma. Tumour Biol. doi:10.1007/s13277-013- 0717-z
26. Liu W, O'Donnell MA, Chen X, Han R, Luo Y (2009) Recombinant bacillus Calmette-Guérin (BCG) expressing interferon-alpha 2B enhances human mononucle ar cell cytotoxicity against bladder cancer cell lines in vitro. Cancer Immunol Immunother 58(10):1647-1655
27. Meyer-Siegler KL, Cox J, Leng L, Bucala R, Vera PL (2010) Macrophage migration inhibitory factor anti-thrombin III complexes are decreased in bladder cancer patient serum: complex formation as a mechanism of inactivation. Cancer Lett 290(1):49-57
28. Okamoto M, Oyasu R (1997) Transformation in vitro of a nontumorigenic rat urothelial cell line by tumor necrosis factor-alpha. Lab Invest 77(2):139-144
29. Okamoto M, Kawai K, Reznikoff CA, Oyasu R (1996) Transformation in vitro of a nontumorigenic rat urothelial cell line by hydrogen peroxide. Cancer Res 56(20):4649-4653
30. Parada B, Sereno J, Reis F, Teixeira-Lemos E, Garrido P, Pinto AF, Cunha MF, Pinto R, Mota A, Figueiredo A, Teixeira F (2009) Anti-inflammatory, anti-proliferative and antioxidant profiles of selective cyclooxygenase-2 inhibit ion as chemoprevention for rat bladder carcinogenesis. Cancer Biol Ther 8(17):1615-1622
31. Robert-Koch-Institut (2010) Krebs in Deutschland. Berlin, pp 84-88
32. Saban MR, Sferra TJ, Davis CA, Simpson C, Allen A, Maier J, Fowler B, Knowlton N, Birder L, Wu XR, Saban R (2010) Neuropilin-VEGF signaling pathway acts as a key modulator of vascular, lymphatic, and inflammatory cell responses of the bladder to intravesical BCG treatment. Am J Physiol Renal Physiol 299(6):F1245-F1256
33. Sabichi AL Lee JJ Grossman HB Liu S Richmond E Czerniak BA De La Cerda J Eagle C Viner JL Palmer JL Lerner SP 2011) A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer. Cancer Prev Res (Phila) 4 10 1580-1589
34. Said N, Theodorescu D (2012) RhoGDI2 suppresses bladder cancer metastasis via reduction of inflammation in the tumor microenvironment. Oncoimmunology 1(7):1175-1177
35. Said N, Sanchez-Carbayo M, Smith SC, Theodorescu D (2012) RhoGDI2 suppresses lung me tastasis in mice by reducing tumor versican expression and macrophage infiltration. J Clin Invest 122(4):1503-1518
36. Said N, Frierson HF, Sanchez-Carbayo M, Brekken RA, Theodorescu D (2013) Loss of SPARC in bladder cancer enhances carcinogenesis and progression. J Clin Invest. doi:10.1172/JCI64782
37. Saito K, Urakami S, Komai Y, Yasuda Y, Kubo Y, Kitsukawa S, Okubo Y, Yamamoto S, Yonese J, Fukui I (2012) Impact of C-reactive protein kinetics on survival of patients with advanced urothelial carcinoma treated by second-line chemotherapy with gemcitabine, etoposide and cisplatin. BJU Int 110(10):1478-1484
38. Siemes C, Vissser LE, Coebergh JW, Splinter TA, Witteman JC, Uitterlinden AG, Hofman A, Pols HA, Stricker BH (2006) C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam study. J Clin Oncol 24(33):5216-5222
39. St Hill CA (2011) Interactions between endothelial selectins and cancer cells regulate metastasis. Front Biosci 16:3233-3251
40. Stenzl A , Hennenlotter J, Schilling D (2008) Can we still afford bladder cancer? Curr Opin Urol 18(5):488-492
41. Stenzl A, Cowan NC, De Santis M, Kuczyk MA, Merseburger AS, Ribal MJ, Sherif A, Witjes JA (2011) Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 59(6):1009-1018
42. Thanan R, Murata M, Ma N, Hammam O, Wishahi M, El Leithy T, Hiraku Y, Oikawa S, Kawanishi S (2012) Nuclear localization of COX-2 in relation to the expression of stemness markers in urinary bladder cancer. Mediators Inflamm 2012:165879.doi:10.1155/2012/165879
43. Theodorescu D, Sapisono LM, Conaway MR, Oxford G, Hampt on GM, Frierson HF Jr (2004) Reduced expression of metastasis suppressor RhoGDI2 is associated with decreased survival for patients with bladder cancer. Clin Cancer Res 10(11):3800-3806
44. Trichopoulos D, Psaltopoulou T, Orfanos P, Trichopoulou A, Boffetta P (2006) Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol Biomarkers Prev 15(2):381-384
45. Trikha M, Corringham R, Klein B, Rossi JF (2003) Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 9(13):4653-4665
46. van der Horst G, Bost L, van der Pluijm G (2012) Epithelial plasticity, cancer stem cells, and the tumor-supportive stroma in bladder carcinoma. Mol Cancer Res 10(8):995-1009
47. Wight TN (2002) Versican: a v ersatile extracellular matrix proteoglycan in cell biology. Curr Opin Cell Biol 14(5):617-623